Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PenumbraPEN +0.57%88 EV-to-OCF is 44.20 as of Aug. 03, 2026, which is 26% below its 10-year median of 59.83. GuruFocus rates PEN with a GF Score™ of 88/100 and a GF Value™ of $331.77 (Fairly Valued). The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Penumbra ranks worse than 89.57% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Penumbra's Enterprise Value is $12,277 Mil.
Penumbra's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $278 Mil. Therefore, Penumbra's EV-to-OCF for today is 44.20.
The historical rank and industry rank for Penumbra's EV-to-OCF or its related term are showing as below:
PEN'
s EV-to-OCF Range Over the Past 10 Years
Min: -10212.85 Med: 59.83 Max: 1163.1
Current: 44.2
During the past 13 years, the highest EV-to-OCF of Penumbra was 1163.10. The lowest was -10212.85. And the median was 59.83.
PEN's EV-to-OCF is ranked worse than 89.57% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.89
vs PEN: 44.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Penumbra's share price for today is $323.02.
Penumbra's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Penumbra EV-to-OCF Related Terms
Penumbra EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Penumbra's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Penumbra's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Penumbra EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Penumbra's EV-to-OCF falls into.
Penumbra's current Enterprise Value is $12,277 Mil.
Penumbra's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $278 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Penumbra (PEN) has a EV-to-OCF of 44.20 as of Aug. 03, 2026. This is 26% below median its historical median of 59.83. According to the industry distribution chart, Penumbra ranks #764 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 89.6%.
Is Penumbra's EV-to-OCF too high?
Penumbra's current EV-to-OCF of 44.20 is 26% below median its 10-year median of 59.83. The Medical Devices & Instruments industry median EV-to-OCF is 7.89. Penumbra's value of 44.20 is 460.2% above this industry median. Based on the distribution chart, Penumbra ranks #764 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Penumbra has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's EV-to-OCF compare to PODD and GMED?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #764 out of 853 companies for EV-to-OCF. This places Penumbra in the lower half of its industry. The industry median EV-to-OCF is 7.89. Penumbra's value of 44.20 is 460.2% above this benchmark. While the company's 10-year median is 59.83 vs. the industry median of 7.89, Penumbra has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Penumbra's current EV-to-OCF of 44.20 is 460.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Penumbra's current EV-to-OCF is 44.20, which is 26% below median its own 10-year median of 59.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $331.77, compared to a current price of $323.02 — trading 2.6% below its estimated fair value. The current EV-to-OCF is 44.20, which is 26% below median its 10-year median of 59.83 and 460.2% above the Medical Devices & Instruments industry median of 7.89. Penumbra's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Penumbra (PEN), the current EV-to-OCF is 44.20 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Penumbra (PEN) Overvalued in 2026?
Based on GuruFocus' analysis, Penumbra stock appears to be undervalued.
The current stock price of $323.02 is trading 2.6% below its estimated GF Value™ of $331.77.
GuruFocus considers Penumbra to be Fairly Valued.
Key valuation signals for PEN:
EV-to-OCF: 44.20 (26% below median its 10-year median of 59.83)
GF Value™: $331.77 vs. price of $323.02 (2.6% below fair value)
Industry Position: 460.2% above the Medical Devices & Instruments median (#764 of 853)
No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
88GF Score
Get the complete analysis for PEN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEN has been successfully added to your 
